Ipamorelin is a synthetic pentapeptide growth hormone-releasing peptide (GHRP) and selective agonist of the ghrelin receptor (GHS-R1a), originally developed by Novo Nordisk in Denmark and first characterised in a landmark 1998 paper in the European Journal of Endocrinology by Raun and colleagues
Stop taking this medicine immediately and consult a physician, dentist, or pharmacist if any of the following occur
Takes about 5 minutes no waiting rooms, no insurance hassle
PubMed Sikiric, P., Separovic, J., Anic, T., Buljat, G., Mikus, D., Seiwerth, S., Grabarevic, Z., Stancic-Rokotov, D., Pigac, B., Hanzevacki, M., Marovic, A., Rucman, R., Petek, M., Ziger, T., Sebecic, B., Zoricic, I., Turkovic, B., Aralica, G., Perovic, D., Duplancic, B., Lovric-Bencic, M., & Rotkvic, I